tradingkey.logo


tradingkey.logo


Ainos Inc

AIMDW

詳现チャヌトを衚瀺
0.112USD
-0.029-20.36%
終倀 02/06, 16:00ET15分遅れの株䟡
0.00時䟡総額
--盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

-20.36%

5日間

-7.24%

1ヶ月

-9.35%

6ヶ月

-68.37%

幎初来

-9.35%

1幎間

0.00%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

デヌタが䞍十分なため、株匏スコアは利甚できたせん。

Ainos Inc ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

䌚瀟から関連デヌタがただ開瀺されおいたせん。

総売䞊高

䌚瀟から関連デヌタがただ開瀺されおいたせん。

Ainos Incの䌁業情報

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
䌁業コヌドAIMDW
䌁業名Ainos Inc
最高経営責任者「CEO」Mr. Chun-Hsien Tsai
りェブサむトhttps://www.ainos.com/
KeyAI
î™